{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-056227","form_type":"8-K","ticker":"IXHL","cik":"0001873875","company_name":"Incannex Healthcare Inc.","filed_at":"2026-05-14T11:30:31+00:00","discovered_at":"2026-05-14T11:35:00.255655+00:00","generated_at":"2026-05-14T11:37:10.397549+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Incannex commences DReAMzz study of IHL-42X for obstructive sleep apnea","bullets":["All 14 clinical trial sites identified; site contracting underway; import/export permits secured.","Study is a crossover dose optimization to de-risk Phase III pathway for IHL-42X.","Previously reported Phase II RePOSA showed statistically significant AHI reductions and improved oxygenation.","FDA granted Fast Track designation for IHL-42X in OSA.","Manufacturing of clinical trial supply completed; global distribution partner onboarded."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-056227","json":"https://secwatch.observer/filing/0001213900-26-056227.json","markdown":"https://secwatch.observer/filing/0001213900-26-056227.md","text":"https://secwatch.observer/filing/0001213900-26-056227.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873875/000121390026056227/0001213900-26-056227-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873875/000121390026056227/ea0290292-8k_incannex.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T11:37:10.397549+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}